Enabling discovery, development, and translation of treatments for cognitive dysfunction in depression workshop summary

Major depressive disorder (MDD) is recognized worldwide as a major cause of disability, morbidity, and mortality. According to the World Health Organization, unipolar depressive disorders affect more than 150 million people around the world and represent the leading cause of years lost due to disabi...

Full description

Main Authors: Bain, Lisa J. (Author), Stroud, Clare (Author)
Corporate Authors: Enabling Discovery, Development, and Translation of Treatments for Cognitive Dysfunction in Depression (Workshop) (2015, Washington, D.C.), Institute of Medicine (U.S.) Forum on Neuroscience and Nervous System Disorders, Institute of Medicine (U.S.) Forum on Drug Discovery, Development, and Translation
Format: eBook
Language:English
Published: Washington, DC National Academies Press [2015], 2015
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02846nam a2200349 u 4500
001 EB001839876
003 EBX01000000000000001003865
005 00000000000000.0
007 tu|||||||||||||||||||||
008 180702 r ||| eng
020 |a 030937393X 
020 |a 9780309373937 
100 1 |a Bain, Lisa J.  |e [author] 
245 0 0 |a Enabling discovery, development, and translation of treatments for cognitive dysfunction in depression  |h Elektronische Ressource  |b workshop summary  |c Lisa Bain and Clare Stroud, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine, The National Academies of Sciences, Engineering, and Medicine 
260 |a Washington, DC  |b National Academies Press  |c [2015], 2015 
300 |a 1 PDF file (xii, 77 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Depressive Disorder, Major / therapy 
653 |a Depressive Disorder, Major / complications 
653 |a Cognition Disorders / complications 
653 |a Cognition Disorders / therapy 
700 1 |a Stroud, Clare  |e [author] 
710 2 |a Enabling Discovery, Development, and Translation of Treatments for Cognitive Dysfunction in Depression (Workshop) (2015, Washington, D.C.) 
710 2 |a Institute of Medicine (U.S.)  |b Forum on Neuroscience and Nervous System Disorders 
710 2 |a Institute of Medicine (U.S.)  |b Forum on Drug Discovery, Development, and Translation 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
500 |a Title from PDF title page 
856 |u http://www.ncbi.nlm.nih.gov/books/NBK305332  |3 Volltext 
082 0 |a 610 
520 |a Major depressive disorder (MDD) is recognized worldwide as a major cause of disability, morbidity, and mortality. According to the World Health Organization, unipolar depressive disorders affect more than 150 million people around the world and represent the leading cause of years lost due to disability among both men and women. In the United States alone, nearly 8 percent of persons over the age of 12 report current depression. MDD has long been defined primarily as a mood disorder. However, more recently people have begun to recognize effects on cognition as a major contributor to the disablement that accompanies depression and to consider this an underrecognized treatment target for depression. To explore how best to enable the discovery, development, and translation of treatments for cognitive dysfunction in depression, including a focus on the regulatory path forward, the Institute of Medicine's Forum on Neuroscience and Nervous Disorders convened key stakeholders at a workshop in February 2015. This report summarizes the presentations from expert speakers and discussions among workshop participants